Klaria Pharma Holding AB (publ.) (KLAR.ST) Stock Analysis & AI Equity Report
Klaria Pharma Holding AB (publ.) (KLAR.ST) overview
Klaria Pharma Holding AB (publ.) (KLAR.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Klaria Pharma Holding AB (publ.) reported revenue of SEK 2.2m and operating profit of SEK -31.2m; the year-end share price was 0.34 SEK and market capitalisation was SEK 41.7m. Klaria Pharma Holding AB (publ.) is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Klaria Pharma Holding AB (publ.)'s valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-03. Data will be refreshed during report generation.
About Klaria Pharma Holding AB (publ.)
Klaria Pharma Holding AB develops and commercialises oral transmucosal drug-delivery films based on a patented alginate platform. Its portfolio has included products for migraine, cancer-related pain, opioid overdose, cannabinoids and anaphylactic shock. The company has also described a recent strategic focus on indications where its films could replace injections or nasal sprays and address unmet patient needs.
Generate the Klaria Pharma Holding AB (publ.) report
Klaria Pharma Holding AB (publ.) is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Klaria Pharma Holding AB (publ.) and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.